nach oben

Clinical Drug Investigation

Erschienen in:

01.05.2019 | Systematic Review

Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review

verfasst von: Young R. Lee, Michael Sadanand Seth, Dylan Soney, Hanyu Dai

Erschienen in: Clinical Drug Investigation | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Sepsis and septic shock are inflammatory disorders associated with high rates of mortality. Patients with sepsis and septic shock frequently become tachycardic as a result of the utilization of vasopressor therapy and cardiac overcompensation owing to hypotension, predisposing patients to an increased risk of atrial fibrillation. Previously, it was thought that beta-blocker therapy in patients with sepsis would exacerbate hypotension; however, recent studies have shown that may not be the case.

Objective

This review aims to ascertain whether beta-blocker therapy reduces heart rate in patients with sepsis without a corresponding decrease in blood pressure, and if beta-blockade has a beneficial effect on mortality.

Methods

Several databases including Cochrane, EMBASE, PubMed, SCOPUS, and Web of Science were scoured for trials pertaining to the utilization of beta-blockers in sepsis and septic shock, and trials that were either prospective or controlled were included in this review.

Results

In the initial search, 1839 articles were found, and those were subsequently reduced to 14 trials (five randomized controlled trials, nine non-randomized trials) that were deemed appropriate for inclusion in this review. All included trials displayed beneficial effects on heart rate without any detriments to blood pressure. Of the six trials that assessed mortality, four showed substantial benefits.

Conclusion

The majority of the trials assessed in this review displayed beneficial results for beta-blocker use in patients with sepsis. However, owing to the deficit of large-scale randomized controlled trials addressing this topic, further research is needed to ensure the veracity of these results.

Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318(13):1241–9. https://doi.org/10.1001/jama.2017.13836.CrossRefPubMedPubMedCentral

Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31:1250–6.CrossRefPubMed

Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55. https://doi.org/10.1378/chest.101.6.1644.CrossRefPubMed

Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045. https://doi.org/10.1038/nrdp.2016.45.CrossRefPubMedPubMedCentral

Suzuki T, Suzuki Y, Okuda J, et al. Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. J Intensive Care. 2017;5:22. https://doi.org/10.1186/s40560-017-0215-2.CrossRefPubMedPubMedCentral

Kuipers S, Klein Klouwenberg PM, Cremer OL. Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. Crit Care. 2014;18(6):688. https://doi.org/10.1186/s13054-014-0688-5.CrossRefPubMedPubMedCentral

Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552. https://doi.org/10.1097/CCM.0000000000002255.CrossRefPubMed

Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32(9):1928–48. https://doi.org/10.1097/01.CCM.0000139761.05492.D6.CrossRefPubMed

Sander O, Welters ID, Foëx P, Sear JW. Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med. 2005;33(1):81–8. https://doi.org/10.1097/01.CCM.0000150028.64264.14.CrossRefPubMed

10.

Chacko CJ, Gopal S. Systematic review of use of β-blockers in sepsis. J Anaesthesiol Clin Pharmacol. 2015;31(4):460–5. https://doi.org/10.4103/0970-9185.169063.CrossRefPubMedPubMedCentral

11.

Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://www.handbook.cochrane.org. Accessed 13 Feb 2019.

12.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097.CrossRefPubMedPubMedCentral

13.

Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock a randomized clinical trial. JAMA. 2013;310(16):1683–91. https://doi.org/10.1001/jama.2013.278477.CrossRefPubMed

14.

Yang S, Liu Z, Yang W, et al. Effects of the β-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(10):714–7. https://doi.org/10.3760/cma.j.issn.2095-4352.2014.10.007.CrossRefPubMed

15.

Wang Z, Wu Q, Nie X, Guo J, Yang C. Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig. 2015;35(11):707–16. https://doi.org/10.1007/s40261-015-0325-3.CrossRefPubMed

16.

Xinqiang L, Weiping H, Miaoyun W, et al. Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(9):759–63. https://doi.org/10.3760/cma.j.issn.2095-4352.2015.09.012.CrossRefPubMed

17.

Wang S, Li M, Duan J, et al. Effect of esmolol on hemodynamics and clinical outcomes in patients with septic shock [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29(5):390–5. https://doi.org/10.3760/cma.j.issn.2095-4352.2017.05.002.CrossRefPubMed

18.

Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg. 1972;104(1):46–51.CrossRefPubMed

19.

Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery. 2006;139(5):686–94. https://doi.org/10.1016/j.surg.2005.10.010.CrossRefPubMed

20.

Balik M, Rulisek J, Leden P, et al. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wien Klin Wochenschr. 2012;124:552–6. https://doi.org/10.1007/s00508-012-0209-y.CrossRefPubMed

21.

Morelli A, Donati A, Ertmer C, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. J Crit Care Med. 2013;41(9):2162–8. https://doi.org/10.1097/CCM.0b013e31828a678d.CrossRef

22.

Tao Y, Jingyi W, Xiaogan J, Weihua L, Xiaoju J. Effect of esmolol on fluid responsiveness and hemodynamic parameters in patients with septic shock [in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(11):885–9. https://doi.org/10.3760/cma.j.issn.2095-4352.2015.11.004.CrossRefPubMed

23.

Du W, Wang XT, Long Y, Liu DW. Efficacy and safety of esmolol in treatment of patients with septic shock. Chin Med J. 2016;129:1658–65. https://doi.org/10.4103/0366-6999.185856.CrossRefPubMedPubMedCentral

24.

Morelli A, Singer M, Ranieri VM, et al. Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med. 2016;42:1528–34. https://doi.org/10.1007/s00134-016-4351-2.CrossRefPubMed

25.

Shang X, Wang K, Xu J, et al. The effect of esmolol on tissue perfusion and clinical prognosis of patients with severe sepsis: a prospective cohort study. Biomed Res Int. 2016;2016:1–7. https://doi.org/10.1155/2016/1038034.CrossRef

26.

Fuchs C, Wauschkuhn S, Scheer C, et al. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth. 2017;119(4):616–25. https://doi.org/10.1093/bja/aex231.CrossRefPubMed

27.

Gorczynski RJ. Basic pharmacology of esmolol. Am J Cardiol. 1985;56(11):3F–13F. https://doi.org/10.1016/0002-9149(85)90910-5.CrossRefPubMed

28.

Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clin Pharmacokinet. 2012;51(6):347–56. https://doi.org/10.2165/11631590-000000000-00000.CrossRefPubMed

29.

Lindsay CA, Barton P, Lawless S, et al. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr. 1998;132(2):329–34.CrossRefPubMed

Titel: Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review
verfasst von: Young R. Lee
Michael Sadanand Seth
Dylan Soney
Hanyu Dai
Publikationsdatum: 01.05.2019
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 5/2019
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-019-00762-z

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects

Chronic Use of β-Blockers and the Risk of Parkinson’s Disease

The Combination of Lithium and ACE Inhibitors: Hazardous, Critical, Possible?

Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report of an Adolescent Girl

Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus